

The Diflunisal Trial

John Berk, MD
Boston Medical Center

October 29, 2011



Familial Amyloid Polyneuropathy

Basis: **Misfolding of variant transthyretin (TTR)**

Factory: **Liver, eye, brain**

Genetics: **Autosomal dominant inheritance**

Features: **Sensory and motor peripheral neuropathy**
Autonomic neuropathy
orthostasis
GI dysmotility
Infiltrative cardiomyopathy
Renal disease

Outcome: **Death 7-15 years after presentation**




Transthyretin (TTR)

Trans =

thy =

retin =



transport

thyroid hormone

retinoic acid

Gene therapy: Liver Transplantation

- 1990 Karolinska Institute, Sweden
- 1991 Deaconess Hospital, Boston MA
- FAP World Transplant Registry: 20-year experience
 - 1789 OLT (FAPWTR : 31 December 2009)
 - 92.3% 5-year survival (Am J Transplant 2007)
 - 46 variant TTR genotypes
 - 19 OLT + OHT

Post Liver Transplant Problems

Progressive heart thickening

1997 Dubrey et al (Transplantation 64:74-80)

- 45% increasing LVH – non-V30M


2002 Olofsson et al (Transplantation)

- V30M ATTR patients


Ocular disease

Arrhythmias

Peripheral neuropathy



Transthyretin (TTR)





Diflunisal (Dolobid) IND 68092



- modified aspirin-like chemical
- Non-Steroid Anti-Inflammatory Drug (NSAID)
- High blood concentrations and minimal side effects





Familial Amyloid Polyneuropathy

Basis: Misfolding of variant transthyretin (TTR)

Genetics: Autosomal dominant inheritance
> 100 variant TTR genes – destabilize tetramer

Features: Sensory and motor peripheral neuropathy
Autonomic neuropathy

orthostasis

GI dysmotility

Infiltrative cardiomyopathy

Renal disease

Outcome: Death 7-15 years after presentation



Peripheral Neuropathy in FAP

Disease model: **Peripheral neuropathy in diabetes mellitus**

Microscopic tissue changes

Peripheral & autonomic neuropathies

Neurologic Impairment Score + 7 (NIS+7) : Peter Dyck, Mayo Clinic

Nerve Conduction Velocities


Computer driven Sensory Testing

Muscle strength & Reflex Assessment

Heart rate variation with deep breathing

EUROPE









Clinical Trials



- Autosomal dominant genetics = family disease
- Participating in a clinical trial
 - Close follow up by disease experts
 - Careful monitoring of drug effects & side-effects
 - Collection and analysis of data → approved new Rx



CONCLUSIONS



- Get tested -- know your genetics
- Be part of the solution → participate in trials
- Encourage your physicians to contact FAP experts and refer to amyloid programs